DOP2023000106A - Construcciones de anticuerpos anti-vegf y métodos relacionados para el tratamiento de los síntomas asociados al schwannoma vesticular - Google Patents
Construcciones de anticuerpos anti-vegf y métodos relacionados para el tratamiento de los síntomas asociados al schwannoma vesticularInfo
- Publication number
- DOP2023000106A DOP2023000106A DO2023000106A DO2023000106A DOP2023000106A DO P2023000106 A DOP2023000106 A DO P2023000106A DO 2023000106 A DO2023000106 A DO 2023000106A DO 2023000106 A DO2023000106 A DO 2023000106A DO P2023000106 A DOP2023000106 A DO P2023000106A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- treatment
- construct
- schwannoma
- aav
- vesticular
- Prior art date
Links
- 208000007538 neurilemmoma Diseases 0.000 title 1
- 206010039667 schwannoma Diseases 0.000 title 1
- 108091026890 Coding region Proteins 0.000 abstract 2
- 206010011878 Deafness Diseases 0.000 abstract 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 2
- 230000010370 hearing loss Effects 0.000 abstract 2
- 231100000888 hearing loss Toxicity 0.000 abstract 2
- 208000016354 hearing loss disease Diseases 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 208000014070 Vestibular schwannoma Diseases 0.000 abstract 1
- 208000004064 acoustic neuroma Diseases 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063120189P | 2020-12-01 | 2020-12-01 | |
US202163152832P | 2021-02-23 | 2021-02-23 | |
PCT/US2021/061205 WO2022119839A1 (fr) | 2020-12-01 | 2021-11-30 | Constructions d'anticorps anti-vegf et procédés associés pour le traitement de symptômes associés au neurinome de l'acoustique |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2023000106A true DOP2023000106A (es) | 2023-07-16 |
Family
ID=80034771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2023000106A DOP2023000106A (es) | 2020-12-01 | 2023-05-26 | Construcciones de anticuerpos anti-vegf y métodos relacionados para el tratamiento de los síntomas asociados al schwannoma vesticular |
Country Status (16)
Country | Link |
---|---|
US (1) | US20230295287A1 (fr) |
EP (1) | EP4255570A1 (fr) |
JP (1) | JP2023551533A (fr) |
KR (1) | KR20230117179A (fr) |
AU (1) | AU2021391433A1 (fr) |
CA (1) | CA3197936A1 (fr) |
CL (1) | CL2023001561A1 (fr) |
CO (1) | CO2023007191A2 (fr) |
CR (1) | CR20230228A (fr) |
DO (1) | DOP2023000106A (fr) |
EC (1) | ECSP23049000A (fr) |
IL (1) | IL303317A (fr) |
MX (1) | MX2023006451A (fr) |
PE (1) | PE20240115A1 (fr) |
TW (1) | TW202237644A (fr) |
WO (1) | WO2022119839A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112020012336A2 (pt) | 2017-12-19 | 2021-03-30 | Akouos, Inc. | Administração de anticorpos terapêuticos mediada por aav para o ouvido interno |
WO2023150142A1 (fr) * | 2022-02-02 | 2023-08-10 | Akouos, Inc. | Constructions d'anticorps anti-vegf et méthodes associées pour le traitement de symptômes associés au schwannome vestibulaire |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0173552B1 (fr) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Composés recombinants d'ADN et l'expression de polypeptides comme le tPA |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
US6268213B1 (en) | 1992-06-03 | 2001-07-31 | Richard Jude Samulski | Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy |
US5869305A (en) | 1992-12-04 | 1999-02-09 | The University Of Pittsburgh | Recombinant viral vector system |
US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
US5741683A (en) | 1995-06-07 | 1998-04-21 | The Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
US6001650A (en) | 1995-08-03 | 1999-12-14 | Avigen, Inc. | High-efficiency wild-type-free AAV helper functions |
US6207457B1 (en) * | 1995-09-08 | 2001-03-27 | Avigen, Inc. | Targeted nucleotide sequence delivery and integration system |
WO1998010088A1 (fr) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Procede inductible de production de virus adeno-associes recombines au moyen de la polymerase t7 |
DE69829891T2 (de) | 1997-04-07 | 2005-10-06 | Genentech, Inc., South San Francisco | Anti-VEGF Antikörper |
AU728220B2 (en) | 1997-04-14 | 2001-01-04 | Cell Genesys, Inc. | Methods for increasing the efficiency of recombinant AAV product |
US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
US6146874A (en) | 1998-05-27 | 2000-11-14 | University Of Florida | Method of preparing recombinant adeno-associated virus compositions |
CA2348382C (fr) | 1998-11-10 | 2013-09-17 | The University Of North Carolina At Chapel Hill | Vecteurs de papirovirus chimeriques et procedes de production et d'administration connexes |
DE60139471D1 (de) | 2000-06-01 | 2009-09-17 | Univ North Carolina | Verfahren und zusammensetzungen zur kontrollierter abgabe von rekombinant parvovirus vektoren |
EP2305299B1 (fr) | 2001-05-31 | 2017-03-01 | GlaxoSmithKline Biologicals SA | Particules de replicon d'alphavirus chimerique |
DE60233061D1 (de) | 2001-09-06 | 2009-09-03 | Alphavax Inc | Alphavirus replikon-vektorsysteme |
NZ532635A (en) | 2001-11-13 | 2007-05-31 | Univ Pennsylvania | A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method |
PT1453547T (pt) | 2001-12-17 | 2016-12-28 | Univ Pennsylvania | Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas |
AU2003274397A1 (en) | 2002-06-05 | 2003-12-22 | University Of Florida | Production of pseudotyped recombinant aav virions |
ES2648241T3 (es) | 2003-09-30 | 2017-12-29 | The Trustees Of The University Of Pennsylvania | Clados de virus adenoasociados (AAV), secuencias, vectores que contienen el mismo, y usos de los mismos |
US7557197B2 (en) | 2004-01-28 | 2009-07-07 | Oregon Health & Science University | Human soluble neuropilin-1 primary polyadenylation signal and uses thereof |
WO2006012414A2 (fr) | 2004-07-20 | 2006-02-02 | Critical Therapeutics, Inc. | Nouveau signal de polyadenylation utilise dans l'expression de vecteurs |
ES2525067T3 (es) | 2005-04-07 | 2014-12-17 | The Trustees Of The University Of Pennsylvania | Método de incremento de la función de un vector de AAV |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
WO2007120542A2 (fr) | 2006-03-30 | 2007-10-25 | The Board Of Trustees Of The Leland Stanford Junior University | Bibliothèque de capsides aav et protéines de capsides aav |
NZ590074A (en) | 2008-07-08 | 2012-12-21 | Abbott Lab | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
EP2443150B1 (fr) | 2009-06-17 | 2015-01-21 | AbbVie Biotherapeutics Inc. | Anticorps anti-vegf et leurs utilisations |
IN2012DN02737A (fr) | 2009-09-01 | 2015-09-11 | Abbott Lab | |
KR20140015139A (ko) | 2009-10-15 | 2014-02-06 | 애브비 인코포레이티드 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
CA2807014A1 (fr) | 2010-08-03 | 2012-02-09 | Abbvie Inc. | Immunoglobulines a double domaine variable et utilisations associees |
EP2831225A1 (fr) | 2012-03-26 | 2015-02-04 | The United States of America, As Represented by the Secretary, Dept. of Health & Human Services Office of Technology Transfer | Administration d'arn encapsulé à des cellules de mammifères |
US20150147317A1 (en) | 2012-06-01 | 2015-05-28 | Momenta Pharmaceuticals, Inc. | Methods related to bevacizumab |
CA2911087A1 (fr) | 2013-04-30 | 2014-11-06 | Harish Shandilya | Nouveau procede de clonage, d'expression et de purification pour la preparation de ranibizumab |
HUE052676T2 (hu) * | 2013-10-11 | 2021-05-28 | Massachusetts Eye & Ear Infirmary | Eljárások õsi vírusszekvenciák elõrejelzésére és alkalmazásaik |
WO2017050825A1 (fr) | 2015-09-21 | 2017-03-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Procédé pour quantifier le bévacizumab |
GB201518979D0 (en) | 2015-10-27 | 2015-12-09 | Univ Leuven Kath | Treatment of hepatic steatosis related oligo-ovulation |
EP3452103A1 (fr) * | 2016-04-15 | 2019-03-13 | The Trustees Of The University Of Pennsylvania | Composition pour le traitement de la dégénérescence maculaire liée a l'âge exsudative |
BR112020012336A2 (pt) * | 2017-12-19 | 2021-03-30 | Akouos, Inc. | Administração de anticorpos terapêuticos mediada por aav para o ouvido interno |
US20210093734A1 (en) * | 2018-02-20 | 2021-04-01 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-realted macular degeneration |
EP3880826A4 (fr) * | 2018-11-07 | 2022-08-24 | Akouos, Inc. | Utilisation de vecteurs viraux adéno-associés pour corriger des défauts de gène/exprimer des protéines dans des cellules ciliées et de soutien dans l'oreille interne |
-
2021
- 2021-11-30 PE PE2023001738A patent/PE20240115A1/es unknown
- 2021-11-30 MX MX2023006451A patent/MX2023006451A/es unknown
- 2021-11-30 WO PCT/US2021/061205 patent/WO2022119839A1/fr active Application Filing
- 2021-11-30 AU AU2021391433A patent/AU2021391433A1/en active Pending
- 2021-11-30 CA CA3197936A patent/CA3197936A1/fr active Pending
- 2021-11-30 TW TW110144619A patent/TW202237644A/zh unknown
- 2021-11-30 EP EP21848203.2A patent/EP4255570A1/fr active Pending
- 2021-11-30 CR CR20230228A patent/CR20230228A/es unknown
- 2021-11-30 KR KR1020237022061A patent/KR20230117179A/ko unknown
- 2021-11-30 IL IL303317A patent/IL303317A/en unknown
- 2021-11-30 JP JP2023533228A patent/JP2023551533A/ja active Pending
-
2023
- 2023-04-13 US US18/134,095 patent/US20230295287A1/en active Pending
- 2023-05-26 DO DO2023000106A patent/DOP2023000106A/es unknown
- 2023-05-31 CO CONC2023/0007191A patent/CO2023007191A2/es unknown
- 2023-05-31 CL CL2023001561A patent/CL2023001561A1/es unknown
- 2023-06-29 EC ECSENADI202349000A patent/ECSP23049000A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CL2023001561A1 (es) | 2023-12-01 |
CR20230228A (es) | 2023-07-18 |
US20230295287A1 (en) | 2023-09-21 |
JP2023551533A (ja) | 2023-12-08 |
EP4255570A1 (fr) | 2023-10-11 |
WO2022119839A1 (fr) | 2022-06-09 |
MX2023006451A (es) | 2023-06-15 |
CO2023007191A2 (es) | 2023-06-20 |
ECSP23049000A (es) | 2023-07-31 |
CA3197936A1 (fr) | 2022-06-09 |
TW202237644A (zh) | 2022-10-01 |
PE20240115A1 (es) | 2024-01-22 |
IL303317A (en) | 2023-07-01 |
AU2021391433A1 (en) | 2023-06-22 |
KR20230117179A (ko) | 2023-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2023007191A2 (es) | Construcciones de anticuerpos anti-vegf y métodos relacionados para el tratamiento de los síntomas asociados al schwannoma vestibular | |
BR112022011421A2 (pt) | Inibidores da proteína mutante kras | |
AR114541A1 (es) | Constructos de anticuerpos para cldn18.2 y cd3 | |
AR083740A1 (es) | Anticuerpos dkk1 (dickkopf-1) y metodos de uso | |
AR083847A1 (es) | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 | |
MX2020011828A (es) | Anticuerpos anti proteina alfa reguladora de se?ales (sirpa) y metodos de uso de los mismos. | |
CL2021001162A1 (es) | Proteínas de fusión fc il-22 y métodos de uso. (divisional de solicitud 202001944) | |
ES2689746T3 (es) | Anticuerpos monoclonales contra la claudina-18 para el tratamiento de cáncer | |
EA201990179A1 (ru) | Новый природный белок и его применение | |
AR058983A1 (es) | Metodos y composiciones para el tratamiento de enfermedades alergicas | |
BR112021019520A2 (pt) | Composição farmacêutica, método para tratar a síndrome de hunter e uso de uma composição farmacêutica | |
PE20211708A1 (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anticgrp o anti-cgrp-r | |
MX2021002299A (es) | Anticuerpos de anti-cd33 y metodos para usarlos. | |
CL2022003147A1 (es) | Composiciones y métodos para tratar pérdida auditiva asociada con gjb2 | |
CO2019013220A2 (es) | Virus oncolíticos y método | |
AR085167A1 (es) | Polipeptidos de porphyromonas gingivalis, metodo de tratamiento, uso, anticuerpo y kit | |
CO2023013500A2 (es) | Anticuerpos anti-cd19 y estructuras car-t | |
AR124186A1 (es) | Construcciones de anticuerpos anti-vegf y métodos relacionados para el tratamiento de los síntomas asociados al schwannoma vestibular | |
CL2023000492A1 (es) | Vector de poxviridae recombinante que expresa moléculas coestimuladoras | |
BR112022021006A2 (pt) | Métodos para reduzir ou prevenir a colonização de clostridioides difficile | |
ECSP22049399A (es) | C?lula vector adyuvante artificial con contenido de ny?eso?1 para usar en el tratamiento del c?ncer | |
PE20230090A1 (es) | Anticuerpos contra el factor de las celulas madre y metodos de uso de ellos | |
CL2020003220A1 (es) | Nueva proteína con propiedades antiinflamatorias | |
AR116876A1 (es) | Vacuna de ibv 4/91 con proteína espicular heteróloga | |
CO2023007325A2 (es) | Composiciones y métodos para tratar la pérdida de audición y/o la pérdida de visión asociada a clrn1 |